Seo Dong-Wan, Li Hongmei, Guedez Liliana, Wingfield Paul T, Diaz Tere, Salloum Rita, Wei Bei-yang, Stetler-Stevenson William G
National Cancer Institute, Center for Cancer Research, Vascular Biology Faculty and Laboratory of Pathology, Extracellular Matrix Pathology Section, National Institutes of Health, Bethesda, MD 20892, USA.
Cell. 2003 Jul 25;114(2):171-80. doi: 10.1016/s0092-8674(03)00551-8.
Tissue inhibitors of metalloproteinases (TIMPs) suppress matrix metalloproteinase (MMP) activity critical for extracellular matrix turnover associated with both physiologic and pathologic tissue remodeling. We demonstrate here that TIMP-2 abrogates angiogenic factor-induced endothelial cell proliferation in vitro and angiogenesis in vivo independent of MMP inhibition. These effects require alpha 3 beta 1 integrin-mediated binding of TIMP-2 to endothelial cells. Further, TIMP-2 induces a decrease in total protein tyrosine phosphatase (PTP) activity associated with beta1 integrin subunits as well as dissociation of the phosphatase SHP-1 from beta1. TIMP-2 treatment also results in a concomitant increase in PTP activity associated with tyrosine kinase receptors FGFR-1 and KDR. Our findings establish an unexpected, MMP-independent mechanism for TIMP-2 inhibition of endothelial cell proliferation in vitro and reveal an important component of the antiangiogenic effect of TIMP2 in vivo.
金属蛋白酶组织抑制剂(TIMPs)可抑制基质金属蛋白酶(MMP)的活性,而MMP活性对于与生理和病理组织重塑相关的细胞外基质周转至关重要。我们在此证明,TIMP-2在体外可消除血管生成因子诱导的内皮细胞增殖,在体内可消除血管生成,且与MMP抑制无关。这些作用需要α3β1整合素介导TIMP-2与内皮细胞的结合。此外,TIMP-2可导致与β1整合素亚基相关的总蛋白酪氨酸磷酸酶(PTP)活性降低,以及磷酸酶SHP-1与β1解离。TIMP-2处理还会导致与酪氨酸激酶受体FGFR-1和KDR相关的PTP活性同时增加。我们的研究结果确立了TIMP-2在体外抑制内皮细胞增殖的一种意外的、不依赖MMP的机制,并揭示了TIMP2在体内抗血管生成作用的一个重要组成部分。